相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Praluzatamab Ravtansine, a CD166-Targeting Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Valentina Boni et al.
CLINICAL CANCER RESEARCH (2022)
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Matteo Duca et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Structural study of ponatinib in inhibiting SRC kinase
Ming Guo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Chiara Corti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment
Chaoyu Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
Jong-Ho Cha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4
Min Shao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Ji Young Kim et al.
ONCOGENE (2022)
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
Lisa A. Carey et al.
NPJ BREAST CANCER (2022)
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
Yi-Zhou Jiang et al.
CELL RESEARCH (2021)
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer
Yuan Yuan et al.
ONCOLOGIST (2021)
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Kartik Anand et al.
SCIENTIFIC REPORTS (2021)
Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
Maojun Zhou et al.
AGING-US (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
Filipa Lynce et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Antibody-drug conjugates: Recent advances in linker chemistry
Zheng Su et al.
ACTA PHARMACEUTICA SINICA B (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer
Michel Demeule et al.
CANCER SCIENCE (2021)
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Michael L. Maitland et al.
CLINICAL CANCER RESEARCH (2021)
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study
Linda T. Vahdat et al.
NPJ BREAST CANCER (2021)
Bispecific Antibodies for Triple Negative Breast Cancer
Sundee Dees et al.
TRENDS IN CANCER (2021)
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy
Xuanmao Jiao et al.
BREAST CANCER RESEARCH (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
Christian M. Seitz et al.
ONCOIMMUNOLOGY (2020)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
Meng Xu et al.
CLINICAL BREAST CANCER (2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer
Hang-Ping Yao et al.
DRUG DISCOVERY TODAY (2020)
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
Jennifer Y. Ge et al.
NATURE COMMUNICATIONS (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Celine Nicolazzi et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Jin Sun Lee et al.
CANCERS (2020)
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer A Phase 3 Randomized Clinical Trial
Ke-Da Yu et al.
JAMA ONCOLOGY (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Byoung Chul Cho et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Retinoblastoma protein expression and its predictors in triple-negative breast cancer
Jaymin M. Patel et al.
NPJ BREAST CANCER (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
Heng Wei et al.
FRONTIERS IN IMMUNOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma
Dan T. Vogl et al.
BLOOD (2020)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro et al.
BREAST CANCER RESEARCH (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-β and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort
Alexander Spira et al.
CANCER RESEARCH (2020)
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
Alexandra Canonici et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer
Elie Hatem et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Nicole M. Kettner et al.
CLINICAL CANCER RESEARCH (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
M. Oliveira et al.
ANNALS OF ONCOLOGY (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
Wei Wen et al.
CELLS (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype
Demin Cai et al.
NATURE COMMUNICATIONS (2019)
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
Lei Nie et al.
NATURE COMMUNICATIONS (2019)
Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite
Wei-Siang Liao et al.
ACTA BIOMATERIALIA (2019)
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
Takuro Yamamoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Yan Liu et al.
AGING-US (2019)
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Peter A. Fasching et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Sonia Pernas et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling
Pernilla Roswall et al.
NATURE MEDICINE (2018)
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
Xiujuan Wu et al.
NATURE COMMUNICATIONS (2018)
Peptide density targets and impedes triple negative breast cancer metastasis
Daxing Liu et al.
NATURE COMMUNICATIONS (2018)
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
Daichao Wu et al.
CHEMICAL COMMUNICATIONS (2018)
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials
Hope S. Rugo et al.
CLINICAL BREAST CANCER (2018)
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer
Wenyu Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
Pedro Miguel Lacal et al.
PHARMACOLOGICAL RESEARCH (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Adriana Matutino et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
Jennifer R. Diamond et al.
BREAST CANCER RESEARCH (2018)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
M. Martin et al.
ANNALS OF ONCOLOGY (2017)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2017)
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
N. C. Synnott et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
Sacituzumab govitecan activity in advanced breast cancer
Talha Khan Burki
LANCET ONCOLOGY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Merino et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Marc Damelin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Heat Shock Proteins and Cancer
Jianming Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice
Kwang Hwa Jung et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects
Hongyan Jia et al.
DRUG RESISTANCE UPDATES (2017)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
Pau Castel et al.
CANCER CELL (2016)
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients
Winston W. Tan et al.
CLINICAL BREAST CANCER (2016)
Cyclin-dependent kinase pathways as targets for women's cancer treatment
Gottfried E. Konecny
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson et al.
CANCER DISCOVERY (2016)
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
Uddalak Bharadwaj et al.
ONCOTARGET (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
Fabrice Andre et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
F. Caiazza et al.
BRITISH JOURNAL OF CANCER (2015)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
Herbert I. Hurwitz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Robert M. Sharkey et al.
CLINICAL CANCER RESEARCH (2015)
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
Khanh Do et al.
INVESTIGATIONAL NEW DRUGS (2015)
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
Melinda L. Telli et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Xi-Chun Hu et al.
LANCET ONCOLOGY (2015)
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer
Katherine M. Lewis et al.
LUNG CANCER (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Pascal Jezequel et al.
BREAST CANCER RESEARCH (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy
Minhao Fan et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Bevacizumab in Neoadjuvant Chemotherapy Increases the Pathological Complete Response Rate in Patients With Triple-Negative Breast Cancer
Mary Kay Barton
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Johanna Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Neil E. Bhola et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
IAP proteins as targets for drug development in oncology
Laurence Dubrez et al.
ONCOTARGETS AND THERAPY (2013)
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells
Kosuke Yamamoto et al.
BIOCHEMICAL JOURNAL (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer
Robin M. Hallett et al.
SCIENTIFIC REPORTS (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer
Lyndsay V. Rhodes et al.
CANCER RESEARCH (2011)
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
Qian Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Markus K. Muellner et al.
NATURE CHEMICAL BIOLOGY (2011)
A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells
X. T. Zhang et al.
ONCOGENE (2011)
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Hannah Harrison et al.
CANCER RESEARCH (2010)
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
Andrew J. Woodhead et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
Theresa A. DiMeo et al.
CANCER RESEARCH (2009)
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2009)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4
David Padua et al.
CELL (2008)
Molecular definition of breast tumor heterogeneity
Michail Shipitsin et al.
CANCER CELL (2007)
TGFβ:: the molecular Jekyll and Hyde of cancer
Brian Bierie et al.
NATURE REVIEWS CANCER (2006)
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
CA Livasy et al.
MODERN PATHOLOGY (2006)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hsp90: an emerging target for breast cancer therapy
J Beliakoff et al.
ANTI-CANCER DRUGS (2004)
Structural and biochemical basis of apoptotic activation by Smac/DIABLO
JJ Chai et al.
NATURE (2000)
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
CY Du et al.
CELL (2000)
分享论文
